PET radiopharmaceuticals beyond 2-[18F]FDG for the evaluation of multiple myeloma and smoldering multiple myeloma

dc.contributor.author	Travascio, Laura
dc.contributor.author	Morales-Lozano, María-Isabel
dc.contributor.author	Guglielmo, Priscilla
dc.contributor.author	Cimini, Andrea
dc.contributor.author	van-Essen, Martijn
dc.contributor.author	Stavrou, Petros-Z
dc.contributor.author	Vatsa, Rakhee
dc.contributor.author	Grisanti, Fabiana
dc.date.accessioned	2026-03-06T14:09:16Z
dc.date.available	2026-03-06T14:09:16Z
dc.date.issued	2025-07-19
dc.identifier.citation	Travascio L, Morales-Lozano MI, Guglielmo P, Cimini A, Van Essen M, Stavrou PZ, et al. PET radiopharmaceuticals beyond 2-[18F]FDG for the evaluation of multiple myeloma and smoldering multiple myeloma. Clin Transl Imaging. 19 de julio de 2025;13(4):379-99. doi:10.1007/s40336-025-00714-y
dc.identifier.issn	2281-5872
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/24666
dc.language.iso	eng
dc.publisher	SPRINGER-VERLAG ITALIA SRL
dc.rights	Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/deed.es
dc.title	PET radiopharmaceuticals beyond 2-[18F]FDG for the evaluation of multiple myeloma and smoldering multiple myeloma
dc.type	info:eu-repo/semantics/article
dc.relation.publisherversion	https://link.springer.com/10.1007/s40336-025-00714-y
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.identifier.doi	10.1007/s40336-025-00714-y
dc.journal.title	Clinical and Translational Imaging
dc.identifier.essn	2281-7565